Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells 3,372 Shares of Stock

CeriBell (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 3,372 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $15.03, for a total value of $50,681.16. Following the completion of the transaction, the chief executive officer now directly owns 743,079 shares of the company's stock, valued at $11,168,477.37. This trade represents a 0.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, April 23rd, Xingjuan Chao sold 15,628 shares of CeriBell stock. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08.
• On Thursday, April 17th, Xingjuan Chao sold 5,700 shares of CeriBell stock. The stock was sold at an average price of $15.02, for a total value of $85,614.00.

CeriBell Price Performance

Shares of NASDAQ CBLL traded down $0.18 during mid-day trading on Friday, hitting $15.31. 246,142 shares of the company were exchanged, compared to its average volume of 272,868. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75. The business's 50 day moving average is $19.64.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $18.53 million during the quarter, compared to analyst estimates of $17.55 million. Analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Several hedge funds and other institutional investors have recently bought and sold shares of CBLL. Legal & General Group Plc acquired a new stake in shares of CeriBell in the fourth quarter valued at approximately $32,000. Summit Investment Advisors Inc. acquired a new position in shares of CeriBell in the fourth quarter worth $33,000. Tower Research Capital LLC TRC purchased a new stake in CeriBell during the 4th quarter worth about $37,000. BNP Paribas Financial Markets acquired a new stake in shares of CeriBell during the 4th quarter worth about $43,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of CeriBell during the fourth quarter worth about $47,000.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. LADENBURG THALM/SH SH started coverage on CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price for the company. Canaccord Genuity Group restated a "buy" rating and set a $33.00 target price on shares of CeriBell in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $32.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.